Evidence map›Paper›PMID 40521274›Full record

ArticleEuropean urology open science2025

Clinical and Genomic Landscape of

Maximilian Haas, Roman Mayr, Danijel Sikic, Bernd Wullich, Niklas Klümper, Philipp Erben, Ralph Wirtz, Christian Bolenz, Florian Roghmann, Robert Stöhr and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology open science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Maximilian HaasDepartment of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
Roman MayrDepartment of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
Danijel SikicDepartment of Urology and Pediatric Urology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Bernd WullichDepartment of Urology and Pediatric Urology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Niklas KlümperDepartment of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.
Philipp ErbenDepartment of Urology and Pediatric Urology, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany.
Ralph WirtzSTRATIFYER Molecular Pathology, Cologne, Germany.
Christian BolenzDepartment of Urology and Pediatric Urology, University Hospital Ulm, University of Ulm, Ulm, Germany.
Florian RoghmannDepartment of Urology and Pediatric Urology, University of Bochum, Herne, Germany.
Robert StöhrComprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Veronika BahlingerComprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Arndt HartmannComprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Maximilian BurgerDepartment of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
Johannes BreyerDepartment of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
Markus EcksteinComprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
BRIDGE Consortium e.V

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objective: Our aim was to provide a comprehensive analysis of the prevalence of potentially targetable activating Methods: We retrospectively analyzed clinical data and Key findings and limitations: In the study population of 1509 patients, 202 (13%) had stage pTa, 380 (25%) had stage pT1, 258 (17%) had localized muscle-invasive bladder cancer (MIBC), 556 (37%) had locally advanced MIBC, 91 (6.0%) had metastatic UC of the bladder (mUCB), and 22 (1.5%) had metastatic upper tract UC (mUTUC). Of the Conclusions and clinical implications: Patient summary: We analyzed a protein called fibroblast growth factor receptor 3 (FGFR3) in patients with cancer of the urinary tract. We found that more aggressive tumors had fewer genetic changes in FGFR3 in comparison to less aggressive tumors. However, genetic changes in FGFR3 were not related to survival for these patients.

Indexed as

FGFR3 alterationProliferationTargeted therapyTumor growthUrothelial carcinoma

Identifiers

PMID40521274
PMCPMC12162067

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.